Increased Risk of Tuberculosis Disease in Lung Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Retrospective Multicenter Study.

ABSTRACT:

Introduction: The introduction of immune checkpoint inhibitor (ICI) therapy in lung cancer has improved survival rates, leading to its widespread use. However, there has been a recent increase in case reports of tuberculosis (TB) disease occurrence following ICI treatment. The objective of this study was to ascertain whether the incidence of TB disease is elevated in the ICI group compared to the group receiving platinum-based chemotherapy among all lung cancer patients.

Methods

To compare the risk of TB disease occurrence between the ICI group and the Platinum group in lung cancer patients, a retrospective study was conducted using the clinical data warehouse platform of eight university hospitals affiliated with the Catholic Medical Center in South Korea.

Results

Out of

SUBMITTER: Park Y 

PROVIDER: S-EPMC12503494 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature